Skip to main content
. Author manuscript; available in PMC: 2015 Feb 5.
Published in final edited form as: Antivir Ther. 2014 Oct 13;19(0 3):15–29. doi: 10.3851/IMP2897

Table 1.

API volume demand and cost outlays to treat 26 million and 34 million patients

API Daily dose Current best cost/kg, USD million Patient-years per metric ton of API API to treat 26 million adult patients, metric tons API cost to treat 26 million adult patients, USD million API to treat 34 million adult patients, metric tons API cost to treat 34 million adult patients, USD million
EFV+TDF+FTCa
 EFV 600 mg 120 4,566 5,690 683 7,450 894
 TDF 300 mg 240 9,132 2,845 683 3,725 894
 FTC 200 mg 240 13,700 1,900 456 2,480 595
 Total 1,100 mg – – 10,435 1,832 13,655 2,383
RPV+TAF+FTCa
 RPV 25 mg 400b 109,589 237 95 310 124
 TAF 25 mg 400b 109,589 237 95 310 124
 FTC 200 mg 240 13,700 1,900 456 2,480 595
 Total 250 mg – – 2,374 646 3,100 843
Projected cost reduction – – – – 1,186c – 1,540c
a

First-line antiretroviral therapy scenario.

b

Projected active pharmaceutical ingredient (API) price with increased volume demand and optimized processing.

c

Difference between scenario totals. EFV, efavirenz; FTC, emtricitabine; RPV, rilpivirine; TAF, tenofovir alafenamide fumarate; TDF, tenofovir disoproxil fumarate.